Chongqing Zhifei Biological Products Co., Ltd. Class A

Chongqing Zhifei Biological Products Co., Ltd. Class A

SSZSE:300122
13.54
CNY
-0.07
(-0.51%)
-5.89EPS
33.47BMarket Cap
Apr 27Next Earn

Total Valuation

CNY

As of September 30, 2026, Chongqing Zhifei Biological Products Co., Ltd. Class A carries a market capitalization of 33.47B, placing it among publicly traded companies globally. Its enterprise value stands at 40.04B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap33.47B
Enterprise Value40.04B

Important Dates

Chongqing Zhifei Biological Products Co., Ltd. Class A's next confirmed earnings release is scheduled for April 27, 2027.

Earnings Date4/27/2027

Share Statistics

As of September 30, 2026, Chongqing Zhifei Biological Products Co., Ltd. Class A has 2.39B shares outstanding.

Shares Outstanding2.39B

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 4.26, and the price-to-book ratio stands at 2.21.

PS Ratio4.26
PB Ratio2.21
P/TBV Ratio2.69

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 5.10 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 40.04B versus a market cap of 33.47B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales5.10

Financial Position

As of September 30, 2026, Chongqing Zhifei Biological Products Co., Ltd. Class A maintains a current ratio of 2.92, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 56.14, indicating elevated leverage, while an interest coverage ratio of -50.68 demonstrates limited ability to service its debt obligations.

Current Ratio2.92
Quick Ratio0.47
Debt / Equity56.14
Debt / EBITDA-0.52
Interest Coverage-50.68

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Chongqing Zhifei Biological Products Co., Ltd. Class A posted a negative return on equity (ROE) of -63.04, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -38.28, reflecting losses generated across the asset base. The company generates approximately 1.25M in revenue per employee across its workforce of 6,292.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-63.04
Return on Assets (ROA)-38.28
Revenue Per Employee1.25M
Employee Count6,292.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Chongqing Zhifei Biological Products Co., Ltd. Class A recorded an income tax benefit of -2.60B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -16.71B and -14.08B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-2.60B

Stock Price Statistics

CNY

As of the close on November 17, 2026, Chongqing Zhifei Biological Products Co., Ltd. Class A's stock has declined approximately 36.25% over the past 52 weeks. The 50-day moving average sits at 13.32, while the 200-day moving average is 14.23.

52-Week Price Change-36.25%
50-Day Moving Average13.32
200-Day Moving Average14.23

Income Statement

CNY

Over the twelve months ended September 30, 2026, Chongqing Zhifei Biological Products Co., Ltd. Class A generated 7.85B in revenue and converted that into -14.08B in net income, yielding earnings per share of -5.89. EBITDA reached -16.66B, while operating income came in at -2.65B.

Revenue7.85B
Gross Profit643.08M
Operating Income-2.65B
Pretax Income-16.71B
Net Income-14.08B
EBITDA-16.66B
EBIT-16.66B
Earnings Per Share (EPS)-5.89

Balance Sheet

CNY

As of September 30, 2026, Chongqing Zhifei Biological Products Co., Ltd. Class A holds 2.32B in cash and equivalents against 8.65B in total debt, resulting in a net debt position of 4.16B. Total book value stands at 15.16B, with working capital of 9.53B providing operational flexibility.

Cash & Cash Equivalents2.32B
Total Debt8.65B
Net Debt4.16B
Equity (Book Value)15.16B
Book Value Per Share6.33
Working Capital9.53B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-451.16M

Margins

Over the twelve months ended September 30, 2026, Chongqing Zhifei Biological Products Co., Ltd. Class A posted a gross margin of 8.19, reflecting its pricing power and cost economics. The operating margin of -33.68 and net profit margin of -179.28 provide insight into operational efficiency.

Gross Margin8.19
Operating Margin-33.68
Pretax Margin-212.80
Profit Margin-179.28
EBITDA Margin-212.18

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Chongqing Zhifei Biological Products Co., Ltd. Class A paid dividends of 0.15 per share. The dividend payout ratio of -2.60 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 19.46, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Chongqing Zhifei Biological Products Co., Ltd. Class A shareholders.

Dividend Per Share0.15
Payout Ratio-2.60
Shareholder Yield19.46

Stock Splits

Chongqing Zhifei Biological Products Co., Ltd. Class A's most recent stock split took place on June 16, 2023 with a 2:3 split ratio.

Last Split Date6/16/2023
Split Ratio2:3

Scores

As of September 30, 2026, Chongqing Zhifei Biological Products Co., Ltd. Class A has an Altman Z-Score of 2.81, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.81